BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mortezaee K. Redox tolerance and metabolic reprogramming in solid tumors. Cell Biol Int 2021;45:273-86. [PMID: 33236822 DOI: 10.1002/cbin.11506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Mortezaee K, Majidpoor J, Kharazinejad E. Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated. Med Oncol 2022;39:193. [PMID: 36071302 DOI: 10.1007/s12032-022-01801-0] [Reference Citation Analysis]
2 Li X, Peng X, Zhang C, Bai X, Li Y, Chen G, Guo H, He W, Zhou X, Gou X. Bladder Cancer-Derived Small Extracellular Vesicles Promote Tumor Angiogenesis by Inducing HBP-Related Metabolic Reprogramming and SerRS O-GlcNAcylation in Endothelial Cells. Adv Sci (Weinh) 2022;:e2202993. [PMID: 36045101 DOI: 10.1002/advs.202202993] [Reference Citation Analysis]
3 Mortezaee K, Majidpoor J. Dysregulated metabolism: A friend-to-foe skewer of macrophages. International Reviews of Immunology. [DOI: 10.1080/08830185.2022.2095374] [Reference Citation Analysis]
4 Mortezaee K, Majidpoor J. NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives. Med Oncol 2022;39:131. [PMID: 35716327 DOI: 10.1007/s12032-022-01735-7] [Reference Citation Analysis]
5 Qiu T, Chen Y, Meng L, Xu T, Zhang H. Identification of a metabolism-related gene signature predicting overall survival for bladder cancer. Genomics 2022;114:110402. [PMID: 35714826 DOI: 10.1016/j.ygeno.2022.110402] [Reference Citation Analysis]
6 Moslehi M, Moazamiyanfar R, Dakkali MS, Rezaei S, Rastegar-Pouyani N, Jafarzadeh E, Mouludi K, Khodamoradi E, Taeb S, Najafi M. Modulation of the immune system by melatonin; implications for cancer therapy. Int Immunopharmacol 2022;108:108890. [PMID: 35623297 DOI: 10.1016/j.intimp.2022.108890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mortezaee K, Majidpoor J. CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives. Front Immunol 2022;13:864298. [DOI: 10.3389/fimmu.2022.864298] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Mortezaee K, Majidpoor J. Checkpoint inhibitor/interleukin-based combination therapy of cancer. Cancer Med 2022. [PMID: 35301813 DOI: 10.1002/cam4.4659] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Monzur S, Hassan G, Afify SM, Kumon K, Mansour H, Nawara HM, Sheta M, Abu Quora HA, Zahra MH, Xu Y, Fu X, Seno A, Wikström P, Szekeres FLM, Seno M. Diphenyleneiodonium efficiently inhibits the characteristics of a cancer stem cell model derived from induced pluripotent stem cells. Cell Biochem Funct 2022. [PMID: 35285948 DOI: 10.1002/cbf.3696] [Reference Citation Analysis]
10 Mortezaee K, Majidpoor J. (Im)maturity in Tumor Ecosystem. Front Oncol 2022;11:813897. [DOI: 10.3389/fonc.2021.813897] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
11 Mortezaee K, Majidpoor J. The impact of hypoxia on immune state in cancer. Life Sci 2021;286:120057. [PMID: 34662552 DOI: 10.1016/j.lfs.2021.120057] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Fontana F, Limonta P. The multifaceted roles of mitochondria at the crossroads of cell life and death in cancer. Free Radic Biol Med 2021;176:203-21. [PMID: 34597798 DOI: 10.1016/j.freeradbiomed.2021.09.024] [Reference Citation Analysis]
13 Mortezaee K, Majidpoor J. Key promoters of tumor hallmarks. Int J Clin Oncol 2021. [PMID: 34773527 DOI: 10.1007/s10147-021-02074-9] [Reference Citation Analysis]
14 Moos WH, Faller DV, Glavas IP, Harpp DN, Kamperi N, Kanara I, Kodukula K, Mavrakis AN, Pernokas J, Pernokas M, Pinkert CA, Powers WR, Steliou K, Tamvakopoulos C, Vavvas DG, Zamboni RJ, Sampani K. Pathogenic mitochondrial dysfunction and metabolic abnormalities. Biochem Pharmacol 2021;193:114809. [PMID: 34673016 DOI: 10.1016/j.bcp.2021.114809] [Reference Citation Analysis]
15 Najafi M, Majidpoor J, Toolee H, Mortezaee K. The current knowledge concerning solid cancer and therapy. J Biochem Mol Toxicol 2021;:e22900. [PMID: 34462987 DOI: 10.1002/jbt.22900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
16 Majidpoor J, Mortezaee K. Interleukin-2 therapy of cancer-clinical perspectives. Int Immunopharmacol 2021;98:107836. [PMID: 34218217 DOI: 10.1016/j.intimp.2021.107836] [Cited by in Crossref: 1] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
17 Mortezaee K. Normalization in tumor ecosystem: Opportunities and challenges. Cell Biol Int 2021. [PMID: 34189798 DOI: 10.1002/cbin.11655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
18 Mortezaee K. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives. Life Sci 2021;277:119627. [PMID: 34004256 DOI: 10.1016/j.lfs.2021.119627] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
19 Majidpoor J, Mortezaee K. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clinical Immunology 2021;226:108707. [DOI: 10.1016/j.clim.2021.108707] [Cited by in Crossref: 13] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
20 Majidpoor J, Mortezaee K. Angiogenesis as a hallmark of solid tumors - clinical perspectives. Cell Oncol (Dordr) 2021;44:715-37. [PMID: 33835425 DOI: 10.1007/s13402-021-00602-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]